CD38 and Burkitt lymphoma: Because daratumumab and isatuximab can also target other CD38-positive B-cell malignancies, we included Daudi cells (Burkitt’s lymphoma) and SU-DHL-8 (diffuse large B cell lymphoma) in our study.